May 10, 2019
CLS Therapeutics Announces Poster Presentation at the Targeting Tumor Heterogeneity Conference

CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Targeting Tumor Heterogeneity Conference organized by the New York Academy of Sciences May 8, 2019, in New York, New York.


Dr. Tetz’s presentation provided an overview of CLS-014, an engineered gene therapy platform addressing unmet need in pancreatic cancer with multiple follow-up extension opportunities. CLS-014 is an AAV vector that targets cell-free DNA, and has the potential for the treatment of solid tumors. The poster presentation also provided an overview of in vivo animal efficacy evaluating CLS-014 for the treatment of pancreatic cancer.

 

Poster Session Presentation Details:

  • Title: Transformative Anticancer Gene Therapy Platform Addressing A Novel Therapeutic Target
  • Poster Number: 26
  • Event: Targeting Tumor Heterogeneity Conference (NYAS)
  • Date: Wednesday, May 8, 2019
  • Event Website: https://www.nyas.org/events/2019/targeting-tumor-heterogeneity/

 

About the CLS Therapeutics:

CLS Translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers, beginning with our first program for pancreatic cancer. PC is the third-leading cause of cancer deaths in the United State with  over  45,000 dying in 2018. It is expected to become the leading cause of cancer mortality already  by 2030. 1-year survival is less than 30%.  5-year survival is less than 8%.

CLS-014 is in silico designed  AAV-based AAV vector encoding  hyperactive human DNase I transgene cassette. Intravenous injection of the vector with a liver specific promoter leads to long term increase of serum  DNase I activity that cleaves cell-free DNA in the blood and therefore affecting primary tumor growth, metastasis and complications associated with NETosis.

CLS-014  is administered as a single injection with any first-line chemotherapeutic agents.

CLS-Therapeutics presented animal data demonstrating the efficacy of CLS-014 in the treatment of  orthotopic pancreatic  mouse xenograft model. CLS-014 alone, inhibited primary tumor growth and metastasis  and  potentiates nab-paclitaxel.

 

About CLS Therapeutics Inc.

CLS-Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.

Aug 12, 2020

NEW YORK, NY /  July, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).

Apr 08, 2020

NEW YORK, NY /  April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.

Aug 06, 2019

CLS Therapeutics Inc., an oncology focused gene therapy company, today announced that their project was selected as one of the 15 finalists to compete for the Boehringer Ingelheim Innovation Prize during the evening of August 15 at NYU Langone Health.